CREB3L3 Genotype

If your triglycerides have been stubbornly high despite a clean diet and exercise, the cause may be written into your DNA. A small but growing body of research links rare loss-of-function variants in the CREB3L3 (cAMP responsive element binding protein 3-like 3) gene to dominantly inherited high triglycerides, sometimes severe enough to push values above 1,000 mg/dL.

This test reads the sequence of your CREB3L3 gene to look for rare variants that disrupt the protein it builds. The result is a one-time genetic read that can explain unexplained high triglycerides in you or your family and shape how aggressively you monitor and treat your lipids for the rest of your life.

What CREB3L3 Does in Your Body

CREB3L3 is a gene active mainly in your liver and intestine, with more recent work also documenting expression in fat tissue. It codes for a transcription factor, which is a protein that turns other genes on and off, and the genes it controls help regulate how your body handles fat after a meal. When CREB3L3 works normally, it helps keep triglyceride levels in check by influencing how the liver packages, clears, and breaks down fat.

When a loss-of-function variant truncates the CREB3L3 protein, that fat-handling control loosens. In particular, triglyceride clearance through an enzyme called lipoprotein lipase becomes less efficient, partly because helper proteins (ApoC2, ApoA4, ApoA5) are made less effectively while an inhibitor (ApoC3) goes up. The result can be triglyceride levels that climb well beyond what is typical, even in someone who eats reasonably and exercises.

Severe Hypertriglyceridemia Risk

The strongest signal in the human data ties CREB3L3 loss-of-function variants to severe high triglycerides. In a study comparing 265 adults of European descent with severe hypertriglyceridemia (triglycerides at or above 885 mg/dL) to 477 people with normal lipids, those with severe hypertriglyceridemia were about 20 times more likely to carry a rare disabling CREB3L3 variant than people with normal lipids.

Source: Dron et al., 2020 (severe hypertriglyceridemia cohort); Cefalu et al., 2015 (family kindreds).

What this means for you: a disabling CREB3L3 variant is one of the few single-gene causes of high triglycerides that can act dominantly, meaning a single copy from one parent can be enough. If your triglycerides have been hard to explain or run in your family, this gene is one of the places to look.

Inheritance and Variable Penetrance

CREB3L3 variants linked to high triglycerides follow an autosomal dominant pattern, meaning a single altered copy from one parent can be enough to raise risk. But not every carrier ends up with high triglycerides. In the kindred carrying the K120fsX20 variant, two adult heterozygous carriers had severe hypertriglyceridemia, while a 13-year-old heterozygous daughter had normal triglyceride levels.

Across the small number of families originally reported with CREB3L3 loss-of-function variants, carriers ranged from completely normal lipids to mild, moderate, and severe high triglycerides; additional families have since been described in the literature. That tells you two things. First, carrying a variant does not guarantee disease. Second, other genes, diet, body weight, alcohol intake, and metabolic health likely shape whether and when the lipid phenotype shows up.

Reconciling the Apparent Paradox

It can feel contradictory that a single variant can produce triglycerides as high as 1,600 mg/dL in one relative and completely normal triglycerides in another. The cleanest way to hold both facts at once is to think of this variant as a predisposition, not a verdict. It raises the ceiling of what your triglycerides can do under metabolic stress, but whether you ever hit that ceiling depends on age, weight, other inherited factors, and lifestyle exposures.

Connections to Other Conditions

Beyond severe hypertriglyceridemia, the human evidence on CREB3L3 thins quickly. Case reports have described an EWSR1-CREB3L3 gene fusion in a rare cancer called sclerosing epithelioid fibrosarcoma. This is an acquired rearrangement found in tumor tissue, not an inherited risk picked up by a CREB3L3 germline genotype test, so a routine genotype result does not address sarcoma risk.

A small chronic pain study reported a modest 1.25-fold increase in CREB3L3 expression in blood cells of patients treated with nerve stimulation, and described the gene as involved in inflammation regulation. The authors explicitly noted it is unknown whether that change has any clinical meaning, so it should not be read as a disease association.

One-Time Result, Lifelong Companion Testing

Your CREB3L3 genotype is fixed at birth and never changes, so this test is run once. The value of the result is not in retesting it, but in using it to drive how often and how seriously you watch downstream markers, particularly triglycerides.

If you carry a disabling CREB3L3 variant, plan for a full fasting lipid panel at least annually, and more often (every 3 to 6 months) when starting or adjusting any treatment. Because the gene shapes triglyceride metabolism specifically, follow the triglyceride number closely rather than waiting for total cholesterol or LDL to change.

Decision Pathway for a Positive Result

If your CREB3L3 genotype shows a rare loss-of-function variant, the next steps are not about retesting the gene. They are about building a workup around it.

• Confirm and characterize your lipid profile: order a fasting lipid panel including triglycerides, and consider adding ApoB (apolipoprotein B) and Lp(a) (lipoprotein little a) to understand your broader cardiovascular picture.
• Look for secondary contributors: triglycerides respond strongly to alcohol, refined carbohydrates, untreated diabetes, hypothyroidism, and certain medications. Check HbA1c (hemoglobin A1c), fasting glucose, TSH (thyroid stimulating hormone), and liver enzymes (ALT and AST) to rule these in or out.
• Involve a lipidologist if triglycerides run high: severe high triglycerides raise the risk of pancreatitis, and dietary changes alone may not be enough. The proband in the Cefalu family was reported to respond well to diet combined with fenofibrate and high-dose omega-3 fatty acids.
• Talk to biological relatives: because the inheritance pattern is dominant, each first-degree relative (parent, sibling, child) has about a 50% chance of carrying the same variant. They can be tested directly for the specific family variant rather than redoing the full gene sequence.

When Results Can Be Misleading

Genetic testing comes with its own set of pitfalls that are different from those for blood tests.

• Variant panel coverage: the assay only reports the variants it is designed to detect. A negative result does not rule out every possible rare variant in CREB3L3, particularly large deletions or variants in regulatory regions outside the coding sequence.
• Ethnic-specific allele frequencies: the largest CREB3L3 study to date was conducted in adults of European descent. Variant frequencies and clinical interpretations may differ in other ancestries, and some variants are simply understudied in non-European populations.
• Variants of uncertain significance: you may receive a CREB3L3 result that flags a change in the gene whose effect on protein function is not yet known. This is not the same as a disabling variant and does not by itself explain high triglycerides.
• Clinical-grade versus direct-to-consumer reports: consumer genetic services typically do not analyze CREB3L3 in clinical detail. A clean direct-to-consumer report should not be read as ruling out a CREB3L3 variant.